Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

03:58 PM EDT, 08/27/2026 (MT Newswires) -- Roivant Sciences (ROIV) said Thursday the FDA approved LISRAYA for adults with dermatomyositis, with the once-daily pill now available in the US, sending its shares up 1.5%. The approval follows the Phase 3 VALOR trial, which showed improvements across disease activity, skin disease, muscle strength and physical function, alongside reduced steroid use. Roivant said the approval provides a new treatment option for adults with dermatomyositis and is continuing to advance brepocitinib in non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris. Price: 37.37, Change: +0.62, Percent Change: +1.67